αO-Conotoxin GeXIVA[1,2] Attenuates Paclitaxel-Induced Neurotoxicity by Suppressing Ferroptosis via the Nrf2/SLC7A11/GSH/GPX4 Pathway
Marine Drugs · 2026
DOI: 10.3390/md24090311 ↗Kurz gefasst
Fachartikel in der Zeitschrift Marine Drugs, 2026. Verfasst von Dongmeng Liu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Tropical Biological Resources of Ministry of Education, School of Pharmaceutical Sciences, Hainan University, Haikou 570228, China. Hauptthemen laut MEDLINE: Paclitaxel, Ferroptosis, Conotoxins, Neurotoxicity Syndromes. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: International Science & Technology Cooperation Program of Hainan Province, Hainan Province Science and Technology Special Fund, National Natural Science Foundation of China.
Abstract (Originalsprache)
Chemotherapy-induced neurotoxicity, affecting both the central and peripheral nervous systems, is a frequent and severe adverse effect of paclitaxel (PAC) treatment with limited therapeutic options. We previously demonstrated that PAC triggers neuronal cell death via ferroptosis. αO-Conotoxin GeXIVA[1,2], a marine-derived peptide, has shown efficacy in alleviating chemotherapy-induced neuropathic pain. In the present study, we investigated whether GeXIVA[1,2] protects neurons from PAC-induced neurotoxicity by suppressing ferroptosis. Using SH-SY5Y and HT-22 neuronal cell lines, we found that GeXIVA[1,2] pretreatment rescued PAC-impaired cell viability without exhibiting cytotoxicity. GeXIVA[1,2] markedly attenuated PAC-induced reactive oxygen species (ROS) overproduction and restored intracellular glutathione (GSH) levels. Mechanistically, PAC suppressed the Nrf2/SLC7A11/GSH/GPX4 ferroptosis-defense pathway, and GeXIVA[1,2] reactivated this axis by upregulating Nrf2, SLC7A11, and GPX4 protein expression. These results reveal a novel ferroptosis-suppressive function of GeXIVA[1,2] in the context of PAC-induced neurotoxicity. Our findings provide a mechanistic foundation for developing GeXIVA[1,2] as a ferroptosis-targeted intervention against chemotherapy-induced neurotoxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Tropical Biological Resources of Ministry of Education, School of Pharmaceutical Sciences, Hainan University, Haikou 570228, China.
- Guangxi Key Laboratory of Special Biomedicine, School of Medicine, Guangxi University, Nanning 530004, China.
- State Key Laboratory of Mechanism and Quality of Chinese Medicine, University of Macau, Macao 999078, China.
ORCID-Profile: Sulan Luo, Jiaolin Bao
Förderung
- International Science & Technology Cooperation Program of Hainan Province
- Hainan Province Science and Technology Special Fund
- National Natural Science Foundation of China
- Hainan Nanhai New Star Project
- the Science and Tech-nology Development Fund
- the State Key Laboratory of Mechanism and Quality of Chinese Medicine, University of Macau
- Science and Technology Development Fund
- State Key Laboratory of Mechanism and Quality of Chinese Medicine, University of Macau
Zitieren
APA
Liu, D., Yu, J., Xu, W., Shen, Y., Feng, X., Li, X., Luo, S., Bao, J., & Ding, R. B. (2026). αO-Conotoxin GeXIVA[1,2] Attenuates Paclitaxel-Induced Neurotoxicity by Suppressing Ferroptosis via the Nrf2/SLC7A11/GSH/GPX4 Pathway. Marine Drugs. https://doi.org/10.3390/md24090311
Vancouver
Liu D, Yu J, Xu W, Shen Y, Feng X, Li X, et al. αO-Conotoxin GeXIVA[1,2] Attenuates Paclitaxel-Induced Neurotoxicity by Suppressing Ferroptosis via the Nrf2/SLC7A11/GSH/GPX4 Pathway. Marine Drugs. 2026. doi:10.3390/md24090311
BibTeX
@article{Liu2026,
author = {Liu, Dongmeng and Yu, Jiaqi and Xu, Weifeng and Shen, Yihong and Feng, Xiaoli and Li, Xiaodan and Luo, Sulan and Bao, Jiaolin and Ding, Ren-Bo},
title = {αO-Conotoxin GeXIVA[1,2] Attenuates Paclitaxel-Induced Neurotoxicity by Suppressing Ferroptosis via the Nrf2/SLC7A11/GSH/GPX4 Pathway},
journal = {Marine Drugs},
year = {2026},
doi = {10.3390/md24090311}
}
EUVIMED